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Abstract. Purpose: For the assessment of folate-based
radiopharmaceuticals, human nasopharyngeal KB carci-
noma cells are traditionally used although nasopharyngeal
cancer is rare. On the other hand, the folate receptor (FR)
is frequently overexpressed on diverse cancer types, the
highest frequency (>90%) being on ovarian carcinomas.
The goal of our study was the in vitro and in vivo
assessment of different FR-positive human carcinoma
cells. In addition, a murine sarcoma cell line was assessed
as a pre-clinical alternative to human xenograft models.
Methods: FR-positive human nasopharyngeal, cervical,
ovarian and colorectal cancer cell lines and the transgenic
mouse sarcoma (24JK-FBP) cell line were targeted with a
novel 99mTc-tricarbonyl folate derivative 2. Comparative
in vitro cell binding studies were carried out under stan-
dardised folate-deficient conditions. In vivo studies were
performed in nude mice and C6 black mice.
Results: The in vitro cell experiments revealed only FR-
specific binding (unspecific <0.02%), ranging from 3.5%
to 52% of complex 2 owing to variable levels of FR
expression of the cell lines. In vivo tumour uptake of
radiotracer 2 varied less than in vitro. It ranged from 0.66±
0.17% ID/g (LoVo) through 1.16±0.64% ID/g (IGROV-1)
and 1.55±0.43% ID/g (24JK-FBP) to 2.33±0.36% ID/g
(KB) 4 h p.i.
Conclusion: These pre-clinical studies indicate that in
vitro data obtained in FR-positive cancer cells do not
necessarily correspond with or predict in vivo radiofolate
uptake in corresponding (xeno)grafts. In addition, the
murine 24JK-FBP cell line proved to be a valuable pre-
clinical alternative to human tumour models.
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Introduction
About 15 years ago, an ovarian cancer-associated, highly
overexpressed antigen (CaMOv18) was identified as a
high-affinity folate-binding protein. This antigen was later
recognised as the folate receptor (FR). The frequent
overexpression of the FR on malignant tissue provides a
unique opportunity to specifically target cancer cells by
virtue of its high affinity for folic acid and folate analogues.
FR targeting has been exemplified using folate conjugates
with a wide variety of diagnostic and therapeutic probes
[1–3] (e.g. chemotherapeutic agents [4], protein toxins [5,
6], antisense oligonucleotides [7, 8], MRI contrast agents
[9] and liposomes [10–12]). Folate radiopharmaceuticals
have been developed as imaging agents of FR-positive
cancers, whereof an 111In- and a 99mTc-radiolabelled
derivative have already proceeded into clinical trials [13–
17]. This highlights the potential of the FR for tumour
targeting and encouraged us to develop and evaluate a novel
organometallic 99mTc-folate radiopharmaceutical for diag-
nosis of FR-positive tumours [18].
The human nasopharyngeal KB carcinoma cell line can
be considered the “gold standard” for FR-targeting studies.
KB cells are traditionally used because of their high and
constant FR expression level [13, 14, 19–24]. However, the
number of patients suffering from nasopharyngeal cancer is
relatively small. In North America, nasopharyngeal cancer
is responsible for only about 0.25% of all cancer types,
which means approximately 1,000 cases per year according
to the American Cancer Society. However, the FR is
overexpressed in a number of other epithelial carcinomas
(e.g. ovarian, endometrial, renal, breast, lung, colorectal),
with ovarian cancer revealing the highest frequency (>90%
of cases) [1, 25]. At the same time, ovarian cancer is the
seventh most common cancer (other than skin cancer) in
women, ranking fourth as the cause of cancer death in
women. The poor prognosis in ovarian cancer is basically
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due to the advanced stage of the disease at the time of a
possible diagnosis. Thus, methods for precise, early and
non-invasive detection of ovarian cancer are of crucial
interest. In this respect, folate radiopharmaceuticals have a
prominent role.
The goals of the present work were twofold: First, we
wished to assess different FR-positive human cancer cell
lines, namely ovarian (IGROV-1, SKOV-3), cervical
(HeLa) and colorectal (HT-29, LoVo) carcinomas. These
data should be compared with those obtained with the most
often used nasopharyngeal KB cancer cell line [4, 25–28].
Secondly, we aimed to evaluate a murine sarcoma cell line
(24JK-FBP [29, 30]), transfected with the human FR-α
gene, for its potential to serve as an inexpensive (with
respect to the mouse strain) alternative to human xenograft
models. For these experiments we employed a novel
organometallic 99mTc(CO)3-folate radiotracer 2 which
proved to target FRs of different cancer cell lines in vitro
and in vivo [31].
Materials and methods
General
Picolylamine mono acetic acid (PAMA)-γ-folate 1 was synthesised
as previously reported [18]. [3′,5′,7,9-3H]Folic acid potassium salt
(37 MBq/ml, 888 GBq/mmol) was purchased from Amersham
Biosciences (Buckinghamshire, UK). The scintillation solution
Ultima Gold, high flash-point LSC cocktail was purchased from
Packard Company (Groningen, the Netherlands). Precursor [99mTc
(CO)3(OH2)3]
+ was prepared using the Isolink-kit (Mallinckrodt-
Tyco, Petten, the Netherlands). [Na][99mTcO4] was eluted from a
99Mo/99mTc generator (Mallinckrodt-Tyco, Petten, the Netherlands)
with a 0.9% saline solution. KB (CCL-17) and A375 cells (CRL-
1619) were purchased from ATCC (American Type Culture Col-
lection, Manassas, USA). HeLa (ACC 57), KB-V1 (ACC 149),
LoVo (ACC 350) and HT-29 (ACC 299) were purchased from
DSMZ (German Collection of Microorganisms and Cell Cultures,
Braunschweig Germany). The ovarian cancer cell lines IGROV-1
and SKOV-3 were kindly provided by Dr. Silvia Miotti (Istituto
Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy) and
Dr. Ellen Vitetta (University of Texas, Dallas, USA), respectively.
The 24JK-FBP cells were obtained from Dr. Patrick Hwu (National
Cancer Insitute, Bethesda, MD, USA). Special RPMI cell culture
medium (without folic acid, vitamin B12, phenol red) was pur-
chased from Cell Culture Technologies GmbH, Gravesano/Lugano,
Switzerland. HPLC analyses were performed on a Merck-Hitachi
L-6200A-system, equipped with an L-3000 tunable absorption
detector, a Berthold LB 508 radiometric detector and an XTerra
(Waters) MS C-18 reversed phase column (5 μm, 15 cm×4.6 mm).
HPLC solvents: aqueous 0.05 M triethylammonium phosphate
buffer, pH 7.0 (solvent A), methanol (solvent B). The HPLC
system started with 100% A with a linear gradient to 20% A and
80% B over 15 min, followed by 5 min of 100% Awith a flow rate
of 1 ml/min. Radioactivity (γ-radiation of 99mTc) was measured
with a γ-counter (Cobra II, Model B 5003, Packard) and (β-radia-
tion of 3H) with a β-counter (TRI-CARB, 1900 TR, Liquid
Scintillation Analyzer, Packard). Protein concentrations for the in
vitro experiments were measured with a microplate reader (Bio-
Rad, Model 550), using a Micro BCA Protein Assay kit (Prod #
23235), Socochim.
Description of the cancer cell lines
IGROV-1 and SKOV-3 cells The IGROV-1 and SKOV-3 cell lines are
human ovarian adenocarcinoma cell lines. It has been reported that
IGROV-1 cells express higher levels of FRs than SKOV-3 [28].
Ovarian cancer has been shown to overexpress the FR with the
highest frequency (>90%) amongst the FR-positive tumour types [1,
25, 32]. For these reasons, ovarian cancers are of primary concern for
FR-targeting strategies, with regard not only to diagnosis but also to
potential therapy with folate radiopharmaceuticals. FR expression in
normal and malignant tissue of the ovary, cervix and uterus was
investigated in detail by Wu et al. [33]. The results of their studies
showed that these tissues present different patterns of FR regulation
in differentiation and malignancy. Quantitatively increased FR
expression associated with foci of poor differentiation could be
shown within an FR-expressing ovarian tumour. In agreement with
these findings, Toffoli et al. found a positive correlation between FR
expression and advanced stage of ovarian tumours [34].
LoVo and HT-29 cells LoVo and HT-29 cell lines are colon
adenocarcinoma cells. Campbell et al. found high levels of FR
expression in LoVo cells, but only low FR expression in HT-29 cells
[26]. It has also been reported that the HT-29 cell line is able to adapt
to the culture conditions by overexpression of FRs [35]. Garin-Chesa
et al. demonstrated that frequency of FR expression is lower in
colorectal carcinoma tissues than in ovarian cancer types [25].
KB, KB-V1 and HeLa cellsKB cells are most often reported in the
literature as a valuable test system for in vitro and in vivo studies of
FR-targeting agents [14, 21, 22, 29, 36, 37]. This cell line is usually
referred to as a human nasopharyngeal carcinoma cell line. The
nasopharynx is an area at the back of the nose towards the base of the
skull. Cancers that develop in this area tend to spread widely and can
hardly be treated by surgery. However, nasopharyngeal cancer is
relatively rare, accounting for only about 0.25% of all cancers in
North America. The KB-V1 cell line is a multidrug-resistant (mdr)
subclone derived from KB-31 cells in 1985. KB-V1 cells strongly
express mdr1 mRNA and protein. Official cell banks concordantly
report that KB cells have to be considered as a HeLa cell subclone
according to the DNA fingerprint. HeLa cells were established from
an epitheloid cervical carcinoma. Cervical cancer begins in the lining
of the cervix, the lower part of the uterus. The development of
cervical cancer often takes a number of years, but can sometimes
happen more quickly. The American Cancer Society predicts that
there will be about 10,000 new cases of invasive cervical cancer in
the United States in 2005.
24JK-FBP cells This is a mouse sarcoma cell line which was
retrovirally transfected with the human FR-α gene. The FR
expression level of this cell line resembles closely that of human
ovarian cancer cells [29].
A375 cells The human A375 cell line is a malignant melanoma
cell line. It has been reported in the literature that this cell line can be
used as a reliable negative control for FR-targeting studies because it
lacks FRs [4].
Cell cultures
Human and murine cancer cell lines were cultured continuously in a
150-cm2 flask as monolayers at 37°C in a humidified atmosphere
containing 7.5% CO2. The cells were cultured in FFRPMI medium
(modified RPMI 1640 medium without folic acid, vitamin B12 and
phenol red), supplemented with 10% heat-inactivated fetal calf
serum (FCS, as the only source of folate), L-glutamine and
antibiotics (penicillin 100 IU/ml, streptomycin 100 μg/ml, fungi-
zone 0.25 μg/ml). Cell culture media such as FCS-supplemented
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FFRPMI are known to feature a final folate concentration of ∼3 nM,
i.e. a value at the low end of the physiological concentration in
human serum [38]. Cell preparation for in vitro experiments was as
follows: 18–20 h prior to each experiment, the cells were seeded in
12-well plates (7–8×105 cells/well) and incubated at 37°C to form
confluent monolayers overnight. Experiments were performed in
triplicate. Cell preparation for in vivo experiments was as follows:
For subcutaneous inoculation of the mice, subconfluent cells were
harvested by treatment with EDTA (1 mM) in phosphate-buffered
saline (PBS, 1x, pH 7.4). The cells were then washed once with
PBS and pelleted by spinning at 1,000×g for 5 min at 20°C. The
cells were resuspended in PBS to the corresponding concentrations
(35–50×106 cells/ml).
Determination of Bmax and KD values of KB, IGROV-1
and 24JK-FBP cells
Inhibition experiments to determine binding constants (KD, Bmax)
were performed according to the following procedure: Cell
monolayers were washed with pure ice-cold PBS, followed by
addition of FFRPMI medium (475 μl, without FCS/L-glutamine/
antibiotics) in each well. 500 μl of the corresponding ice-cold folic
acid solution (10 concentrations ranging from 0.001 μM up to
0.2 μM, prepared in PBS, pH 7.4) was added. The well plates were
pre-incubated at 4°C for 40 min. The solution of 3H-folic acid (25 μl,
∼19 kBq) was added and the well plates incubated again at 4°C for
2 h1. Cells were then washed three times with PBS (pH 7.4, 1 ml) and
the cells were lysed in 1 N NaOH (1 ml), transferred to 4-ml tubes
and homogenised by vortex. The concentration of proteins was
determined in each sample by a Micro BCA Protein Assay kit.
Scintillation solution (4 ml) was added, and the samples were
homogenised and transferred into scintillation flasks. Each sample
was counted for radioactivity in a β-counter. KD and Bmax values had
been determined by converting the raw data from counts per minute
(cpm) bound per mg protein into pmol radiotracer bound per mg
protein, and analysed by Rosenthal plot. The mean values of KD and
Bmax acquired in two independent experiments for each cell line are
shown in Table 1.
Preparation of the radiotracer 2 and solutions for in vitro
and in vivo experiments
99mTc(CO)3-PAMA-γ-folate (2) was synthesised according to the
following procedure: Precursor fac-[99mTc(CO)3(OH2)3]
+ was pre-
pared via the Isolink method [18, 39]. The obtained solution of
fac-[99mTc(CO)3(OH2)3]
+ (100 μl; ∼1 GBq/ml), PBS (pH 7.4,
350 μl) and a stock solution of derivative 1 (50 μl, 10−3 M in PBS)
were mixed in a sealed glass vial. The reaction was heated at 75°C for
30 min to form complex 2 (yield >95%, Fig. 1). Complex 2 was
separated from unlabelled compound 1 by means of HPLC and
diluted in PBS (pH 7.4) to obtain a final concentration of 1 MBq/ml
for in vitro experiments or 3.7 MBq/ml for in vivo experiments. The
complex 2 revealed a high stability in PBS and human plasma over a
period of 24 h at 37°C, as previously demonstrated by our group [18].
Cell uptake in vitro
Cell binding experiments with radiotracer 2 were performed
according to the following procedure: Cell monolayers were rinsed
twice with ice-cold PBS (pH 7.4). Pure FFRPMI medium (975 μl,
without FCS/L-glutamine/antibiotics) or 475 μl FFRPMI and 500 μl
of a solution of folic acid (200 μM) were added into each well. The
well plates were pre-incubated at 37°C for 40 min. Then, a solution
of the 99mTc(CO)3-labelled radiotracer (25 μl, 1 MBq/ml) was added
and the well plates were incubated again at 37°C for 1 h. The cell
monolayers were washed with PBS for determination of total bound
and internalised radiotracers or with stripping buffer (aqueous
solution of 0.1 M acetic acid and 0.15 M NaCl, pH 3) in order to
Fig. 1. Preparation of new, organometallic 99mTc(CO)3-folate
radiotracer 2
Table 1. Bmax and KD values of 3H-folic acid in different FR-positive cell lines
Cell line Bmax (pmol/mg protein) KD (nM)
KB cellsa 11.9 (−12.18 to +35.97) 7.22 (−11.15 to +25.58)
IGROV-1 cellsa 0.09 (−1.11 to +0.28) 3.45 (−28.70 to +35.60)
24JK-FBP cellsa 0.16 (+0.09 to +0.22) 1.24 (−2.95 to +5.43)
aValues shown in parentheses represent the lower and upper limits of the 95% confidence interval; number of experiments =2
1Experiments were performed with 3H-folic acid at 4°C because
under these conditions endocytosis is largely attenuated. Time-
dependent cell binding studies, performed over a period of 4 h
revealed maximal binding after 2 h. Experiments with excess
unlabelled folic acid in order to block FRs revealed negligible
amounts (<0.5%) of unspecific cell binding of 3H-folic acid and
could therefore be neglected (data not shown).
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determine exclusively the internalised fraction. Blocking experi-
ments were performed by pre-incubation of the cells with excess folic
acid (100 μM) in order to saturate FRs. The monolayers were
dissolved in 1 N NaOH (1 ml), transferred to 4-ml tubes and
homogenised by vortex. The samples were counted for radioactivity
using a γ-counter. The concentration of proteins was determined for
each sample by aMicro BCA Protein Assay kit in order to standardise
measured radioactivity in each sample to the averaged content of
proteins in each well. The raw data of measured radioactivity were
converted into percentage of total added radioactivity.
In vivo studies
Four- to 5-week-old female, athymic nude mice (CD1-Foxn1/nu) and
female black mice (C57BL/6N) were purchased from Charles River
Laboratories (Sulzfeld, Germany). Mice were housed under condi-
tions of controlled temperature (26°C and 22°C, respectively),
humidity (68%) and daily light cycle (12 h light/12 h dark). The
animals were exclusively fed with a folate-deficient rodent chow
(in order to reduce their serum folate to a level near that of human
serum) [36]. After an acclimation period of 5–7 days, the mice
were inoculated subcutaneously with 0.1 ml tumour cell suspen-
sion (35–50×106 cells/ml) into the subcutis of the axilla. Radio-
tracer distribution studies were performed 12–14 (or 19–21 days in
the case of IGROV-1 cells) after tumour cell inoculation.
Biodistribution studies were performed in triplicate. The radiotrac-
er 2 (100 μl, 3.7 MBq/ml) was administered via a lateral tail vein.
To competitively block tissue FRs, mice were injected with excess
folic acid (0.25 μmol in PBS, pH 7.4) 5 min prior to the
radiotracer. At the indicated points in time the animals were
sacrificed and dissected. The selected tissues were removed and
weighed, and the radioactivity was counted by a γ-counter to
determine tissue distribution of the radiotracers within the test
animal. The results were tabulated as percentage of the injected
dose per gram tissue (% ID/g), using reference counts from a
definite sample of the original injectate.
Results
In vitro studies
The aim of these screening experiments was the qualitative
evaluation of the in vitro uptake of the 99mTc-folate
radiotracer 2 (Fig. 1) in different FR-expressing cancer cell
lines (for detailed description of the cell lines, see Materials
and methods). A series of FR-positive and FR-negative
human and murine cancer cell lines were tested. Results of
cell binding and internalisation experiments are sum-
marised in Fig. 2. Radioactivity bound to FR-positive KB
and the multiresistant subclone KB-V1 cell lines was found
in the range of 35–50% of total added radioactivity. Among
the human FR-positive ovarian carcinoma cell lines, we
found slightly higher cell binding in IGROV-1 cells
(∼42%) than in SKOV-3 cells (∼26%). Also, for the
human cervical HeLa carcinoma cell line (∼36%) and the
transfected murine sarcoma cell line (∼36%) we found
results in the same range. Colorectal carcinoma cell lines
(LoVo and HT-29) revealed relatively low binding (3–5%
of total added radioactivity). As expected, the FR-negative
A375 cell line was found to bind less than 0.05% of total
added radioactivity. The internalised fraction of the radio-
tracer was determined by washing the cells with stripping
buffer (pH 3), enabling the acid-dependent release of FR-
bound radiotracer on the cell surface. For all FR-positive
cell lines, internalisation amounted to approximately 20–
35% of total cell-associated radioactivity. Blockade of the
receptors with excess folic acid resulted in less than 0.1%
binding of the radiotracer 2 in each of the FR-positive cell
lines. It is noteworthy that the FR-negative A375 could be
readily cultured in folic acid-containing standard medium.
On the other hand, these cells survived for only a short time
in folate-deficient medium in which FR-positive cancer cell
lines could be easily cultured.
In vivo studies
For the in vivo assessment of all FR-positive tumour cell
lines, we performed biodistribution studies in tumour-
bearing mice, 4 h after administration of the radiotracer 2.
Previous in vivo studies in KB tumour-bearing mice have
shown the most favourable tumour accumulation of the
radiotracer at this time after injection.
Compound 2 predominately accumulated in FR-posi-
tive tissues (tumour and kidneys). The amounts of
radioactivity found in non-targeted tissue and organs
were in the same range for all experiments performed
with athymic nude mice (CD1-Foxn1/nu) as well as with
C6 black mice (C57BL/6N). Representatively, the % ID/g
data of radioactivity accumulated in tumours and kidneys
as well as the tumour-to-kidney, tumour-to-blood and
tumour-to-liver ratios are presented in Table 2. Uptake of
radioactivity in KB-V1 tumours (1.48±0.23% ID/g) was
lower than in KB tumours (2.33±0.36% ID/g) and tumour-
to-blood ratios of accumulated radioactivity were also
slightly different (KB-V1: 26.9±18.9 vs KB: 58.0±12.2).
However, tumour-to-kidney ratios of radioactivity were
comparable (KB-V1: 0.12±0.03 vs KB: 0.13±0.02). Data
obtained from HeLa cell tumour-bearing mice (1.31±
Fig. 2. Cell binding, internalisation and competitive inhibition (with
100 μM folic acid) after incubation (1 h at 37°C) of the radiotracer 2,
performed with different FR-positive human and murine cancer cell
lines
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0.06% ID/g) were similar to those of KB-V1 cell tumours,
but lower than in KB tumours, and tumour-to-blood ratios
(21.10±4.60) and tumour-to-kidney (0.08±0.02) ratios
were accordingly reduced. Differences in accumulated
radioactivity found in vitro between the two ovarian
(IGROV-1, SKOV-3) cell lines were less pronounced in
vivo. Tumour uptake of the radiotracer in mice with
IGROV-1 (1.16±0.64% ID/g) and SKOV-3 (1.03±0.18%
ID/g) cell xenografts was found to be in the same range as
in animals with HeLa cell tumours. Tumour-to-blood ratios
were also found to be in the same range (IGROV-1: 23.11±
16.33; SKOV-3: 19.97±5.59). On the other hand, we
observed very low in vivo tumour uptake of the radiotracer
in colorectal LoVo and HT-29 cancers (∼0.6% ID/g),
leading to unfavourably low tumour-to-non-tumour ratios
(tumour-to-blood ratios: 7.69±1.66 and 6.53±1.12; tumour-
to-liver ratios: 0.43±0.15 and 0.30±0.17; tumour-to-kidney
ratios: 0.04±0.01 and 0.06±0.03, respectively). Murine
24JK-FBP sarcoma cells, studied in normal C6 black mice,
revealed highest tumour accumulation of radioactivity
(1.55±0.43% ID/g) amongst all cell lines tested (except KB
cells), and tumour-to-background ratios were comparable
to those obtained in mice bearing nasopharyngeal (KB-
V1), ovarian (IGROV-1, SKOV-3) or cervical (HeLa)
tumour xenografts.
More detailed, time-dependent (1 h, 4 h and 24 h p.i.) in
vivo studies were performed in the two human FR-positive
cell lines KB, IGROV-1 and the murine cell line 24JK-FBP
in athymic nude mice (KB, IGROV-1) and C6 black mice
(24JK-FBP) (Tables 3, 4 and 5). As mentioned before, for
pre-clinical studies a mouse cell line is of high interest for
two reasons: (a) it represents an inexpensive tumour model
because it enables in vivo studies using normal mice
(C57BL/6N) rather than the costly athymic nude mice
necessary for experiments with human tumour xenografts
(e.g. KB); (b) particularly for 24JK-FBP cells, it has been
reported in the literature that their FR level mimics very
well that found in clinically relevant human ovarian cancer
cell lines (e.g. IGROV-1) [29].
Tumour uptake 4 h p.i. of the radiotracer was slightly
lower in IGROV-1 and 24JK-FBP tumours than in KB cell
tumours. Interestingly, accumulation of radioactivity in KB
tumours was highest 4 h p.i. of the radiotracer (2.33±0.36%
ID/g), whereas maximal tumour uptake of radiotracer was
found 1 h p.i. in IGROV-1 (1.94±0.20% ID/g) and 24JK-
FBP cell tumours (1.90±0.09% ID/g). The radiotracer was
efficiently cleared from the bloodstream, resulting in
<0.15% ID/g 4 h after injection of radioactivity. Tumour-
to-blood and tumour-to-liver radioactivity ratios increased
over time and reached maximum values after 24 h (tumour-
to-blood ratio: approx. 100–300 and tumour-to-liver ratio:
approx. 6–25). Tumour-to-kidney ratios were virtually
constant (within the standard deviations) over time for all
types of (xeno)graft. Accumulation of the radiotracer 2 was
reduced to background levels (<0.01% ID/g) in all three
tumour types when excess free folic acid was intravenously
injected 5 min prior to the radiotracer in order to saturate
FRs. These last findings clearly proved that FR-specific
tumour accumulation of the radiotracer also occurs in vivo.
Correlation of tumour size and radiotracer uptake
Tumour size of the KB, IGROV-1 and 24JK-FBP cell
(xeno)grafts varied, even though the number of inoculated
tumour cells and the period of tumour growth were
standardised. Different tumour size/mass can potentially
give rise to artefacts in measured % ID/g values because of
reduced accumulation of radiotracer if cells buried deep
within large tumours become poorly accessible to blood-
borne radiotracers. Therefore, we performed studies in
order to correlated % ID/g values of KB (fast-), 24JK-FBP
(medium-) and IGROV-1 (slow-growing) tumours with the
corresponding tumour sizes. KB tumours grew faster in
vivo than did 24JK-FBP, whereas only slow tumour growth
was observed with IGROV-1 cells, which grew no bigger
than approximately 150 mg even 3 weeks after inoculation
of the tumour cells. Tumour data were obtained from
animals 2 and 3 weeks after inoculation of the cancer cells.
Radioactivity was determined 4 h p.i. of the radiotracer 2.
Figure 3 depicts the percentage injected dose (% ID)
plotted against the corresponding tumour size for each type
of (xeno)graft (30–300 mg). Good linear correlation
(r>0.97) between accumulated radiotracer 2 and the
tumour size was found in all tumour types. Hence, one
can conclude that small variations in the tumour size did
Table 2. Biodistribution of 99mTc(CO)3-PAMA-γ-folate (2) in athymic nude mice bearing human cancer cell xenografts 4 h post injection
Cell line Tumour Kidney Tumour-to-kidney ratio Tumour-to-blood ratio Tumour-to-liver ratio
KB 2.33±0.36 18.48±0.72 0.13±0.02 58.0±12.2 2.53±2.13
KB-V1 1.48±0.23 12.05±0.98 0.12±0.03 26.91±18.92 4.79±3.63
HeLa 1.31±0.06 16.07±3.47 0.08±0.02 21.10±4.60 0.78±0.09
IGROV-1 1.16±0.64 12.75±3.42 0.09±0.03 23.11±16.33 0.99±0.22
SKOV-3 1.03±0.18 8.00±1.70 0.13±0.02 19.97±5.59 0.71±0.26
LoVo 0.66±0.17 16.25±4.11 0.04±0.01 7.69±1.66 0.43±0.15
HT-29 0.67±0.03 12.43±4.80 0.06±0.03 6.53±1.12 0.30±0.17
24JK-FBPa 1.55±0.43 17.13±1.50 0.09±0.03 21.07±12.36 4.88±2.25
Values (% ID/g) represent the mean±SD of data from three animals per cohort
aMouse sarcoma grafts in female black mice (C57BL/6N)
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not influence our results with respect to accumulated
radioactivity, and therefore the results obtained with each
of these tumour cell lines can be compared even if the
tumour masses did not match throughout the experiments.
Discussion
The potential of the novel radiofolate 2 to target KB
carcinoma cells in vitro and in vivo with high FR
specificity was demonstrated previously. Because, overall,
the data were comparable with those reported for other
radiofolates (e.g. 111In-DTPA-folate [13], 99mTc-DTPA-
folate [14]), it is reasonable to assume that the results
reported in the present study are largely transferable to
other (radio)folate derivatives. The experiments using the
radiotracer 2 with various cancer cell lines led to several
interesting observations.
Qualitative in vitro studies showed specific cell binding
of the folate radiotracer 2 in all FR-positive human and
murine cancer cell lines. This was proven in blocking
experiments with excess folic acid for FR saturation, which
Table 3. Time-dependent biodistribution of 99mTc(CO)3-PAMA-γ-folate (2) in KB tumour-bearing mice
99mTc(CO)3-PAMA-γ-folate (2) + Folic acida
1 h 4 h 24 h 4 h
Blood 0.09±0.02 0.04±0.00 0.01±0.00 0.01±0.00
Heart 0.85±0.27 0.32±0.07 0.02±0.02 0.00±0.00
Lung 0.57±0.19 0.33±0.02 0.03±0.00 0.02±0.02
Spleen 0.20±0.03 0.15±0.04 0.01±0.02 0.01±0.01
Kidney 14.37±1.35 18.48±0.72 6.90±0.72 0.06±0.01
Stomach 0.31±0.06 0.63±0.33 3.70±6.37 3.80±5.46
Intestines 1.89±0.37 1.49±0.23 0.76±1.15 0.40±0.45
Liver 0.89±0.31 2.37±2.85 0.10±0.02 0.12±0.02
Muscle 1.06±0.33 0.54±0.05 0.05±0.04 0.04±0.01
Bone 0.76±0.22 0.31±0.07 0.03±0.04 0.01±0.01
Tumour 1.30±0.61 2.33±0.36 1.32±0.17 0.00±0.01
Tumour-to-blood ratio 15.82±11.29 58.0±12.2 255.4±115.4
Tumour-to-liver ratio 1.60±0.81 2.53±2.13 13.77±1.90
Tumour-to-kidney ratio 0.09±0.05 0.13±0.02 0.19±0.04
Values (% ID/g) represent the mean±SD of data from three animals per cohort
a0.25 μmol; injection 5 min before radiotracer 2
Table 4. Time-dependent biodistribution data of 99mTc(CO)3-PAMA-γ-radiotracer (2) in IGROV-1 tumour-bearing mice
99mTc(CO)3-PAMA-γ-folate (2) + Folic acida
1 h 4 h 24 h 4 h
Blood 0.11±0.05 0.06±0.04 0.00±0.00 0.01±0.02
Heart 0.59±0.08 0.20±0.04 0.01±0.00 0.00±0.00
Lung 0.53±0.05 0.35±0.16 0.02±0.00 0.01±0.00
Spleen 0.12±0.05 0.12±0.08 0.00±0.00 0.04±0.06
Kidney 16.97±3.07 12.75±3.42 4.68±0.13 0.09±0.04
Stomach 0.70±0.11 0.42±0.20 0.21±0.24 22.93±23.10
Intestines 8.78±4.23 1.38±0.71 0.04±0.02 0.71±0.75
Liver 4.61±1.51 1.34±1.07 0.02±0.00 0.40±0.45
Muscle 0.72±0.07 0.37±0.11 0.01±0.00 0.00±0.00
Bone 0.31±0.07 0.15±0.03 0.01±0.02 0.00±0.00
Tumour 1.94±0.20 1.16±0.64 0.66±0.06 0.00±0.00
Tumour-to-blood ratio 25.10±10.74 23.11±16.33 102.3±95.8
Tumour-to-liver ratio 0.44±0.03 0.99±0.22 27.00±2.34
Tumour-to-kidney ratio 0.13±0.02 0.09±0.03 0.14±0.00
Values (% ID/g) represent the mean±SD of data from three animals per cohort
a0.25 μmol; injection 5 min before radiotracer 2
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resulted in almost complete inhibition of radiotracer
accumulation in these cancer cell lines. FR specificity
was further corroborated by the observation that FR-
negative cancer cells (A375) were not capable of
accumulating the folate radiotracer 2. However, the fact
that cell-associated radioactivity in vitro varied signifi-
cantly amongst the tested cell lines strongly indicates that
the cell lines reveal different FR expression levels.
Therefore determination of FR expression level (using
3H-folic acid) was carried out in three representative cell
lines (KB, IGROV-1 and 24JK-FBP). It could be shown
that KB cells exhibited a distinctively higher level of
binding sites (approx. two orders of magnitude) than
IGROV-1 or 24JK-FBP cell lines (Table 1).
For the above-mentioned comparative in vitro experi-
ments, all cell lines were cultured under the same
standardised conditions using a folate-deficient cell culture
medium. However, apart from extracellular folate concen-
tration, ingredients of the cell culture medium and duration
of folate-starved conditions (all aspects taken into account
in these experiments), genetic properties of the cell lines
themselves can influence FR expression levels and, as a
consequence, radiotracer uptake. Variable FR expression
levels in different cancer cell lines are also reported in the
literature. Campbell et al. found (via fluorescence-activated
cell sorting) similar FR expression levels in SKOV-3 and
HT-29, higher levels in LoVo cells and very high levels in
HeLa cells [26], whereas our data clearly indicated
significantly higher levels in the ovarian (IGROV-1,
SKOV-3) and cervical (HeLa) cancer cell lines than in
colorectal cancers (Lovo, HT-29). In order to quantitatively
determine FRs in cells and tissues, it is reasonable to use
3H-folic acid since this has many advantages over other
methods (e.g. antibodies [25]), in particular high sensitivity
thanks to the extremely specific binding of 3H-folic acid to
the FR and the fact that only “functional” FRs will be
targeted [32].
It is noteworthy that FR-expressing cell lines exhibited
an unambiguous advantage over FR-negative cells, such as
A375, with regard to proliferation under folate-deprived
conditions: the latter cells could hardly be cultured in
folate-deficient medium. This means that under folate-
starved culture conditions, other folate transport mecha-
nisms (e.g. the ubiquitously distributed reduced folate
carrier) are not sufficient for the accumulation of folates,
necessary for cell survival [40].
Interestingly, variation in tumour-accumulated radioac-
tivity in vivo was not as pronounced as would have been
expected on the basis of the in vitro data. All of the FR-
positive cancer (xeno)grafts were specifically targeted by
the folate radiotracer 2. Most importantly, the in vivo data
Fig. 3. Correlation of tumour-accumulated radioactivity (% ID) and
tumour size (mg): ■ KB tumours (r=0.971), ● 24JK-FBP tumours
(r=0.997), ▲ IGROV-1 tumours (r=0.989)
Table 5. Time-dependent biodistribution data of 99mTc(CO)3-PAMA-γ-radiotracer (2) in 24JK-FBP tumour-bearing mice
99mTc(CO)3-PAMA-γ-folate (2) + Folic acida
1 h 4 h 24 h 4 h
Blood 1.77±2.84 0.11±0.09 0.02±0.02 0.00±0.00
Heart 0.72±0.13 0.15±0.05 0.01±0.02 0.00±0.00
Lung 1.27±0.55 0.35±0.04 0.03±0.01 0.00±0.00
Spleen 0.33±0.27 0.08±0.03 0.01±0.01 0.00±0.00
Kidney 15.25±1.00 17.13±1.50 10.92±3.05 0.08±0.01
Stomach 2.72±0.89 0.73±0.33 0.41±0.48 0.07±0.09
Intestines 24.38±13.82 2.77±1.15 1.52±1.37 0.03±0.04
Liver 6.35±3.17 0.35±0.10 0.12±0.06 0.19±0.26
Muscle 1.03±0.13 0.32±0.03 0.05±0.04 0.06±0.01
Bone 0.76±0.11 0.11±0.04 0.01±0.01 0.00±0.00
Tumour 1.90±0.09 1.55±0.43 0.57±0.04 0.00±0.00
Tumour-to-blood ratio 9.62±8.31 21.07±12.36 97.16±114.46
Tumour-to-liver ratio 0.52±0.20 4.88±2.25 6.01±3.74
Tumour-to-kidney ratio 0.13±0.01 0.09±0.03 0.06±0.02
Values (% ID/g) represent the mean±SD of data from three animals per cohort
a0.25 μmol; injection 5 min before radiotracer 2
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obtained with ovarian (IGROV-1, SKOV-3) and cervical
(HeLa) cancer cell lines revealed that all showed
accumulation in the same range (approx. 1–2% ID/g, 4 h
p.i.), but slightly lower than that in KB tumours. Hence, not
only the most common KB tumour model, but also
clinically relevant tumour types such as ovarian cancer
(the primary targets of folate-based diagnosis or treatment),
can be successfully targeted by folate-based radiotracers.
Data regarding accumulated radioactivity in KB-V1
tumours were also in the same range in vivo. Thus, one
could conclude that the ability of KB cells to express FRs
and their potential to bind folate radiotracers were retained
even in the multiresistant sub-clone KB-V1. It remains to
be investigated whether this result can be generalised to
other multiresistant cancer cell lines. Such properties of
multidrug resistant cancers, which can escape conventional
chemotherapy but are revealed to be sensitive to potential
folate-based (radio)therapy, are of the highest interest.
Even though in vitro colorectal cancers (HT-29, LoVo)
showed significantly lower cell accumulation of radioac-
tivity than KB cells, and are therefore supposed to express
lower FR levels, the corresponding tumour xenografts
revealed reasonable accumulation of radioactivity in vivo.
It is of particular interest for pre-clinical assessment of
folate tracers to recognise that each of the tumour models is
useful in order to obtain conclusive, reproducible and
comparable data, even if tumour masses varied amongst the
individual experiments. Fast tumour growth was observed
for KB and KB-V1 cells, medium growth for SKOV-3,
HeLa, HT-29 and 24JK-FBP cells and only slow tumour
growth for Lovo and IGROV-1 cells. In order to assure
reliability of the % ID/g data in tumour tissue, a careful
analysis of the dependence of tumour mass and % ID was
carried out with three of these cell lines, representative for
each group: fast- (KB), medium- (24JK-FBP) and slow
(IGROV-1)-growing cell lines. The results of this analysis
revealed a linear correlation for all three cell lines. Hence,
artefacts in our % ID/g values can be largely excluded. In
this context, we were also able to demonstrate that the
mouse 24JK-FBP cell line is a valuable alternative to
human FR-positive cell lines and/or xenografts for folate-
based (radio)tracer development. Distribution of the
radiotracer in normal tissues of 24JK-FBP tumour graft-
bearing C6 black mice was comparable to biodistribution
of the radiotracer in athymic nude mice. Thus, mouse
strain-dependent differences could be largely excluded.
The mouse sarcoma cell line is of particular interest for fast
and unproblematic tumour growth, enabling easy practi-
cability and lower cost of in vivo experiments through the
use of normal mice. In addition, it should be mentioned,
that regarding the FR expression level, 24JK-FBP cells
more closely mimic human ovarian cancer cell lines.
Time-dependent in vivo studies, performed with three
selected cell lines (KB, IGROV-1 and 24JK-FBP), revealed
a desirable fast elimination of radioactivity from the
bloodstream. Four hours post injection, radioactivity in
the blood pool was less than 0.15% ID/g. These findings
are in agreement with the literature, where biological half-
lives of several folate conjugates have been reported to be
in the range of only a few minutes as a consequence of their
rapid renal clearance [16, 41]. Such pharmacokinetics are
highly favourable for achieving sufficient contrast between
targeted and non-targeted tissues on images.
Taking into account the relatively small variations in
total tumour uptake observed in vivo between “high FR-
expressing“ (KB) and “low FR-expressing” (LoVo) cell
lines, we conclude that FR expression level is not
necessarily predictive of the success of FR-targeted
radiodiagnosis. However, the findings of this study have
to be considered as pre-clinical results. Whether or not this
conclusion can be transferred to humans will need to be
carefully evaluated. However, if our hypothesis is correct,
radiofolates could be of diagnostic potential for virtually all
FR-positive tumours.
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